# EDGAR Filing Document

**Accession Number:** 0001660046
**File Stem:** 0001213900-26-061760
**Filing Date:** 2026-5
**Character Count:** 10414
**Document Hash:** d997b34186a4dc826757f4694a0a2c4e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-061760.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0001213900-26-061760

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 5

**CONFORMED PERIOD OF REPORT**: 20260528

**FILED AS OF DATE**: 20260528

**DATE AS OF CHANGE**: 20260528

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immuron Ltd
- **CENTRAL INDEX KEY:** 0001660046
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38104
- **FILM NUMBER:** 261028591

**BUSINESS ADDRESS:**
- **STREET 1:** 62 LYGON STREET
- **STREET 2:** LEVEL 3
- **CITY:** CARLTON, VICTORIA
- **STATE:** C3
- **ZIP:** 3053
- **BUSINESS PHONE:** 61 03 9824 5254

**MAIL ADDRESS:**
- **STREET 1:** 62 LYGON STREET
- **STREET 2:** LEVEL 3
- **CITY:** CARLTON, VICTORIA
- **STATE:** C3
- **ZIP:** 3053

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER**

**THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of May 2026

Commission File Number: 001-38104

**<u>IMMURON LIMITED</u>**

(Name of Registrant)

**<u>Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia</u>**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

**IMMURON LIMITED**

**<u>EXPLANATORY NOTE</u>**

Immuron Limited (the "Company") published an announcement (the "Public Notices") to the Australian Securities Exchange on May 28, 2026 titled:

- Response to ASX Price Query

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

**EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit** <br> **Number** | **Description** |
| 99.1 | [Response to ASX Price Query](ea029248101ex99-1.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **IMMURON LIMITED** | **IMMURON LIMITED** |
| Date: May 28, 2026 | By: | /s/ Olga Smejkalova |
|  |  | Olga Smejkalova |
|  |  | Company Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ea029248101_ex99-1img1.jpg)

28 May 2026

Ms Melissa Kostopoulos

Senior Adviser, Listings Compliance (Melbourne)

ASX Limited

Dear Ms Kostopoulos

RE: Immuron Limited ('IMC'): Response to Price Query

I refer to your letter dated 28 May 2026 regarding IMC's Price Query. The Company's responses to the numbered questions set out in the letter are as follows:

1. Is
 IMC aware of any information concerning it that has not been announced to the market which,
 if known by some in the market, could explain the recent trading in its securities?

Immuron Limited (ASX: IMC; NASDAQ: IMRN) (the Company) is not aware of any information concerning it that has not been announced to the market which, if known, would explain the recent trading in the Company 'securities.

2. If
 the answer to question 1 is "no", is there any other explanation that IMC may
 have for the recent trading in its securities?

As previously disclosed in the ASX/NASDAQ announcement lodged on 8 May 2026, the CEO, Steve Lydeamore, delivered a presentation at the Emerging Growth Conference held in the United States.

3. Please
 confirm that IMC is complying with the Listing Rules and, in particular, Listing Rule 3.1 .

The Company confirms that it is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

4. Please
 confirm that IMC's responses to the questions above have been authorised and approved
 under its published continuous disclosure policy or otherwise by its board or an officer
 of IMC with delegated authority from the board to respond to ASX on disclosure matters.

This response has been authorised and approved by the Board of Directors.

Yours Sincerely

Olga Smejkalova

Company Secretary

Level 3, 62 Lygon Street, www.immuron.com Phone: + 61 (0)3 9824 5254 <br> Carlton South, Victoria Facsimile: + 61 (0)3 9822 7735 <br> AUSTRALIA 3053 ABN: 80 063 114 045

![](ea029248101_ex99-1img2.jpg)

28 May 2026

Ms Olga Smejkalova

Company Secretary

Immuron Limited

Level 3, 62 Lygon Street

Carlton, Vic 3053

By email:o.smejkalova@acclime.com

Dear Ms Smejkalova

**Immuron Limited ('IMC'): Price Query**

ASX refers to the following:

A. The
 change in the price of IMC's securities from a low of $0.032 at close of trade yesterday
 27/05/2026 to a high of $0.044 today at the time of writing.

B. The
 significant increase in the volume of IMC's securities traded today.

**Request for information**

In light of this, ASX asks IMC to respond separately to each of the following questions and requests for information:

1. Is
 IMC aware of any information concerning it that has not been announced to the market which,
 if known by some in the market, could explain the recent trading in its securities?

If the answer to question 1 is "yes".

&nbsp;&nbsp;&nbsp;&nbsp;(a) Is
 IMC relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1?
 Please note that the recent trading in IMC's securities would suggest to ASX that such
 information may have ceased to be confidential and therefore IMC may no longer be able to
 rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes",
 you need to contact us immediately to discuss the situation.

&nbsp;&nbsp;&nbsp;&nbsp;(b) Can
 an announcement be made immediately? Please note, if the answer to this question is "no",
 you need to contact us immediately to discuss requesting a trading halt (see below).

&nbsp;&nbsp;&nbsp;&nbsp;(c) If
 an announcement cannot be made immediately, why not and when is it expected that an announcement
 will be made?

2. If
 the answer to question 1 is "no", is there any other explanation that IMC may
 have for the recent trading in its securities?

3. Please
 confirm that IMC is complying with the Listing Rules and, in particular, Listing Rule 3.1.

4. Please
 confirm that IMC's responses to the questions above have been authorised and approved
 under its published continuous disclosure policy or otherwise by its board or an officer
 of IMC with delegated authority from the board to respond to ASX on disclosure matters.

ASX Limited ASX Customer Service Centre 131 279 \| asx.com.au

**2/3**

![](ea029248101_ex99-1img3.jpg)

**When and where to send your response**

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **<u>1:00 PM AEST Thursday, 28 May 2026</u>**.

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, IMC's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require IMC to request a trading halt immediately.

Your response should be sent by e-mail to **<u>ListingsComplianceMelbourne@asx.com.au</u>**<u>.</u> It should not be sent directly to the ASX Market Announcements Office. This is to allow us to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

**Trading halt**

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in IMC's securities under Listing Rule 17.1. If you wish to request a trading halt, you must tell us:

● the
reasons for the trading halt;

● how
long you want the trading halt to last;

● the
event you expect to happen that will end the trading halt;

● that
you are not aware of any reason why the trading halt should not be granted; and

● any
other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts and Voluntary Suspensions*.

**Suspension**

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in IMC's securities under Listing Rule 17.3.1.

**Listing Rules 3.1 and 3.1A**

In responding to this letter, you should have regard to IMC's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*. It should be noted that IMC's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

**Release of correspondence between ASX and entity**

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A. The usual course is for correspondence to be released to the market.

Regards

ASX Compliance

ASX Customer Service Centre 131 279 \| asx.com.au

**3/3**